XT-150-1-0201 Extension: Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs XT-150 (Primary)
- Indications Osteoarthritis; Pain
- Focus Adverse reactions
- Sponsors Xalud Therapeutics
- 06 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 11 Apr 2019 Planned primary completion date changed from 30 Apr 2019 to 30 Sep 2019.
- 15 Feb 2019 Status changed from not yet recruiting to recruiting.